Clinical Trials Browser

Completed × Breast Neoplasms × neratinib × Clear all

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Breast Neoplasms

NCT04388384 2025-08-06

ELEANOR

Breast Neoplasms

NCT03094052 2025-06-26

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

Phase 2 Completed

11 enrolled 12 charts

Breast Neoplasms

NCT04366713 2023-02-10

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Phase 2 Completed

6 enrolled 8 charts

Breast Neoplasms

NCT02236000 2023-01-26

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Phase 1/2 Completed

49 enrolled 17 charts

Breast Neoplasms

NCT02400476 2022-05-06

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Phase 2 Completed

563 enrolled 16 charts

Breast Neoplasms

NCT01670877 2022-04-15

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Phase 2 Completed

56 enrolled 29 charts

Breast Neoplasms

NCT01008150 2021-10-25

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Phase 2 Completed

141 enrolled 16 charts

Breast Neoplasms

NCT00878709 2021-06-11

ExteNET

Phase 3 Completed

2,840 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT01111825 2018-09-26

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Phase 1/2 Completed

99 enrolled 14 charts

Breast Neoplasms

NCT00146172 2018-09-17

Study Evaluating HKI-272 in Tumors

Phase 1 Completed

73 enrolled 20 charts

Breast Neoplasms, Neoplasms

NCT00741260 2018-09-05

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Phase 1/2 Completed

105 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00915018 2018-08-22

NEFERTT

Phase 2 Completed

479 enrolled 13 charts

Breast Neoplasms

NCT00300781 2018-08-14

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Phase 2 Completed

136 enrolled 11 charts

Breast Neoplasms, Neoplasms

NCT00706030 2018-08-09

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Phase 1/2 Completed

92 enrolled 14 charts

Breast Neoplasms

NCT00777101 2018-08-09

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Phase 2 Completed

233 enrolled 16 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00445458 2018-07-26

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Phase 1/2 Completed

110 enrolled 13 charts

Breast Neoplasms, Neoplasms

NCT00398567 2018-07-24

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

Phase 1/2 Completed

45 enrolled 15 charts

Breast Neoplasms

NCT00366600 2017-09-11

Study Evaluating HKI-272 Administered to Healthy Subjects

Phase 1 Completed

Breast Neoplasms

NCT01423123 2014-07-08

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT00708903 2012-05-14

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

Phase 1 Completed

Breast Neoplasms